TD Cowen assumed coverage on shares of Waldencast (NASDAQ:WALD – Free Report) in a research report sent to investors on Monday morning, MarketBeat.com reports. The firm issued a hold rating and a $4.30 target price on the stock.
WALD has been the subject of several other research reports. DA Davidson increased their target price on shares of Waldencast from $7.25 to $7.50 and gave the stock a “buy” rating in a report on Wednesday, December 4th. Canaccord Genuity Group raised their price objective on Waldencast from $5.00 to $6.00 and gave the company a “buy” rating in a report on Friday, November 22nd. Telsey Advisory Group reaffirmed an “outperform” rating and set a $6.00 price target on shares of Waldencast in a research report on Monday, November 18th. Finally, Canaccord Genuity Group started coverage on shares of Waldencast in a research note on Friday, October 25th. They issued a “buy” rating and a $5.00 price target for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.76.
Check Out Our Latest Report on WALD
Waldencast Trading Down 9.5 %
Institutional Trading of Waldencast
Hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. grew its stake in Waldencast by 293.9% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,854 shares of the company’s stock valued at $25,000 after buying an additional 5,114 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Waldencast in the second quarter valued at approximately $37,000. Catalina Capital Group LLC bought a new position in shares of Waldencast during the third quarter worth approximately $58,000. McAdam LLC acquired a new stake in Waldencast during the 3rd quarter worth approximately $62,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Waldencast in the 2nd quarter valued at $85,000. Institutional investors and hedge funds own 41.97% of the company’s stock.
About Waldencast
Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.
Read More
- Five stocks we like better than Waldencast
- When to Sell a Stock for Profit or Loss
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- NYSE Stocks Give Investors a Variety of Quality Options
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Waldencast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waldencast and related companies with MarketBeat.com's FREE daily email newsletter.